Photo by _louisreed from unsplash
Wang: No relevant conflicts of interest. Morrissette: No relevant conflicts of interest. Lieberman: No relevant conflicts of interest. Timlin: No relevant conflicts of interest. Schuster: Nordic Nanovector: Membership on an… Click to show full abstract
Wang: No relevant conflicts of interest. Morrissette: No relevant conflicts of interest. Lieberman: No relevant conflicts of interest. Timlin: No relevant conflicts of interest. Schuster: Nordic Nanovector: Membership on an entity’s Board of Directors or advisory committees; Janssen: Research Funding; Novartis: Research Funding; Genentech: Consultancy; Gilead: Research Funding; Hoffman-LaRoche: Research Funding; Celgene: Consultancy, Research Funding; Phamacyclics: Consultancy, Research Funding. Mato: Gilead: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Pronai Pharmaceuticals: Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Celgene Corporation: Consultancy, TG Therapeutics: Research Funding; Acerta: Research Funding. Jie Wang Jennifer Morrissette David B. Lieberman Colleen Timlin Stephen J. Schuster Anthony R. Mato Center for CLL, and Center for Personalized Diagnostics, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA E-mail: [email protected]
Journal Title: British Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!